Therapeutic benefit of second-look transurethral resection of bladder tumors for newly diagnosed T1 bladder cancer: a single-center experience

Tseng, Wen-Hsin; Liu, Chien‐Liang; Huang, Steven Kuan-Hua; Liao, Alex Chien-Hwa; Kuo, Jinn‐Rung; Hun, Shun-Hsing; Chen, Chun‐Hao; Su, Chin-Chuan; Wang, Jhih-Cheng; Lee, Kau-Han; Shen, Kun‐Hung; Li, Chien‐Feng

doi:10.1007/s11255-019-02172-8

Cited by 9 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 2-year RFS rates were 74.6% and 60% and the PFS rates were 91.2% and 87.5% in groups 1 and 2, respectively (23). These results emphasize the importance of second TURBT in T1 bladder cancer not only for restaging but also for therapeutic benefit (24). Improved CCS and overall survival (OS) were also demonstrated (25).…”

Section: Second Turbt (Re-resection or Re-look Turbt)mentioning

confidence: 70%

Transurethral resection of bladder tumour (TURBT)

Kim

Patel

2020

Transl Androl Urol

View full text Add to dashboard Cite

The goals of transurethral resection of bladder tumour (TURBT) are to identify and eradicate visualized bladder tumour if technically safe and feasible and to obtain a specimen of satisfactory quality to enable accurate histological diagnosis. In the setting of high grade bladder tumour this generally entails the inclusion of detrusor muscle and assessment for the presence of associated carcinoma in situ (CIS), lymphovascular involvement or any variant form of bladder cancer. This will assist in determining risk stratification and prognostication of the bladder cancer and guides further treatment planning. Conversely, if suboptimal TURBT is performed there will be detrimental consequences on patient outcomes in regards to undergrading or understaging, increased recurrence or progression, and subsequently need for further treatments including more invasive interventions. This review article firstly summarises the key principles and complications of TURBT, as well as significance of re-TURBT. We also discuss a number of modifications and advances in detection technology and resection techniques that have shown to improve perioperative as well as pathological and oncological outcomes of bladder cancer. They include enhanced cystoscopy such as blue light cystoscopy (BLC), narrow band imaging (NBI) and en bloc resection of bladder tumour (ERBT) technique using various types of energy source.

show abstract

Section: Second Turbt (Re-resection or Re-look Turbt)mentioning

confidence: 70%

Transurethral resection of bladder tumour (TURBT)

Kim

Patel

2020

Transl Androl Urol

View full text Add to dashboard Cite

show abstract

“…On the other hand, the effect-size for the SLRintervention in that study on both RFS and PFS is larger than the expected differences for those outcome measures between adjuvant instillations with mitomycin and BCG [4]. The remaining evidence for SLR emanates from retrospective data hampered by studying heterogeneous cohorts, being influenced by selection bias, and also showing conflicting results [5][6][7][8][9][10]. However, some of the series included in that evaluation did not use adjuvant BCG instillations, or even no adjuvant instillations at all, and the largest study assessed did not report progression-free survival, the most important outcome measure in stage T1 BCa.…”

Section: Introductionmentioning

confidence: 87%

A population-based study on the effect of a routine second-look resection on survival in primary stage T1 bladder cancer

Bobjer

Hagberg

Aljabery

et al. 2021

Scandinavian Journal of Urology

View full text Add to dashboard Cite

Objective: To assess the value of second-look resection (SLR) in stage T1 bladder cancer (BCa) with respect to progression-free survival (PFS), and also the secondary outcomes recurrence-free survival (RFS), bladder-cancer-specific survival (CSS), and cystectomy-free survival (CFS).Patients and methods: The study included 2456 patients diagnosed with stage T1 BCa 2004-2009 with 5-yr follow-up registration in the nationwide Bladder Cancer Data Base Sweden (BladderBaSe). PFS, RFS, CSS, and CFS were evaluated in stage T1 BCa patients with or without routine SLR, using univariate and multivariable Cox regression with adjustment for multiple confounders (age, gender, tumour grade, intravesical treatment, hospital volume, comorbidity, and educational level). Results: SLR was performed in 642 (26%) individuals, and more frequently on patients who were aged < 75 yr, had grade 3 tumours, and had less comorbidity. There was no association between SLR and PFS (hazard ratio [HR] 1.1, confidence interval [CI] 0.85-1.3), RFS (HR 1.0, CI 0.90-1.2), CFS (HR 1.2, CI 0.95-1.5) or CSS (HR 1.1, CI 0.89-1.4). Conclusions: We found similar survival outcomes in patients with and patients without SLR, but our study is likely affected by selection mechanisms. A randomised study defining the role of SLR in stage T1 BCa would be highly relevant to guide current praxis.

show abstract

“…A prospective study from Taiwan also showed that re-resection identified 18% of residual tumors [39].…”

Section: Second Look At Turbt and Outcomementioning

confidence: 98%

Did the Scientific Innovations in the Management of Non-Muscle Invasive Bladder Cancer Patients Improve the Outcome during the Last 2 Decades?

Alame¹,

Raad²,

Ibrahim³

2022

OJU

View full text Add to dashboard Cite

Objectives: Previous reviews reported the outcome of each scientific modality in the management of T1 high-grade bladder cancer. The objective of this review is to assess and evaluate the available scientific modalities used during the last two decades and determine whether they were able to improve the clinical outcome. Literature Search Methodology: A systematic literature review was conducted from 2000-2020 using PubMed, Medline, Embase, and other database sites looking at randomized controlled trials (RCTs), clinical trials, research, review articles, and original articles addressing the different scientific modalities used to diagnose and manage patients with non-muscle invasive Bladder cancer (NMIBC)during the last 2 decades. More than 573 studies were retrieved following the preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines and PICOS criteria (Population, Intervention, Comparators, Outcomes, and Study design). Only 85 articles were selected for review including 19 prospective trials, 44 RCTs, original articles, research articles, one review article, and clinical trials-Retrospective studies were excluded to limit bias as much as possible in the analysis. Results: Randomized controlled trials (RCTs) have become the gold standard for evaluating the efficacy of new treatments. They are considered the highest standard of evidence-based medicine and are the method of choice. Overall, we selected 85 studies for review, among them 63 prospective trials and RCTs, with a total of 21,895 patients, published between 2000 and 2020. Previously conducted studies have shown that identifying rare histological types with poor prognoses can help improve outcomes, mainly the plasmacytoid How to cite this paper: Alame, W.F., Raad, N. and Ibrahim, S. (2022) Did the Scientific Innovations in the Management of Non-Muscle Invasive Bladder Cancer Patients Improve the Outcome during the Last 2 Decades?

show abstract

Therapeutic benefit of second-look transurethral resection of bladder tumors for newly diagnosed T1 bladder cancer: a single-center experience

Cited by 9 publications

References 27 publications

Transurethral resection of bladder tumour (TURBT)

Transurethral resection of bladder tumour (TURBT)

A population-based study on the effect of a routine second-look resection on survival in primary stage T1 bladder cancer

Did the Scientific Innovations in the Management of Non-Muscle Invasive Bladder Cancer Patients Improve the Outcome during the Last 2 Decades?

Contact Info

Product

Resources

About